We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sales of Unapproved Device Lands Couple in Hot Water

Sales of Unapproved Device Lands Couple in Hot Water

September 18, 2015

A couple has pleaded guilty in a California court to charges related to the sale of an unapproved device that they said could be used as treatment for a range of conditions, including AIDS, worms and cancer.

David and Sandra Perez marketed the Energy Wave over the Internet — an unapproved device that consists of a microcurrent frequency generator, two stainless steel cylinders, two personal application plates and a list of auto codes associated with specific disease conditions, according to court documents.

“Users were provided with an operating manual and a listing of ‘Auto Codes’ that set forth hundreds of digital settings for the device, directed to specific conditions such as abdominal pain, AIDS, diabetes, stroke, ulcer and worms,” according to court documents filed in the U.S District Court for the Southern District of California.

Fines, Other Penalties

David, 60, has admitted to selling the device for $1,200 to $1,500 each, earning gross proceeds of about $271,000. Sandra, 55, shipped the devices and deposited the funds necessary to pay a coconspirator, David Arthur.

In an indictment unsealed earlier this year, Arthur was accused of producing the devices at his residence, which was not registered with the FDA as a manufacturing establishment. He previously pleaded guilty and is awaiting sentencing.

David admitted that he intended to mislead the FDA by attempting to avoid the agency’s oversight of medical claims made regarding the Energy Wave device by maintaining a separate website, rifecodes.com. He would steer customers to the site to obtain the auto codes that allegedly were effective in treating the various conditions.

In a statement, U.S. Attorney Laura Duffy chides the couple, who previously lived in Carlsbad, Calif., but now resides in Oregon, for duping vulnerable elderly patients, many of whom were suffering from incurable diseases.

“Those who are sick and desperate for relief are particularly vulnerable to scams, and we are doing our best to protect them from people who exploit the weak for their own financial gain” she says.

David is scheduled to be sentenced Jan. 11, 2016, and faces up to three years in prison and a $250,000 fine. Sandra already has received a sentence of a year of probation and 100 hours of community service. She also must pay restitution of $1,495 to a buyer of the device. — Elizabeth Hollis

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • EMA logo European Medicines Agency logo

    EMA Reviews GSK’s and Vir’s VIR-7831 for COVID-19

  • CE mark

    Hensler Surgical Technologies Earns CE Mark for Bone-Fusion Device

  • Eli lilly logo

    Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

  • CE mark

    Alimetry Earns CE Mark for Wearable Gastric Disease Diagnostic

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing